Remove 2021 Remove Competition Remove Safety
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires. Competition starts to heat up. Classic treatment options. Two decades of exclusivity.

article thumbnail

Top oncology breakthroughs shared at ESMO 2021

Clarivate

As part of our Drugs to Watch series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate oncology experts sifted through the more than 2,800 abstracts that were accepted for presentation at the ESMO 2021 Virtual Conference and selected their top picks. Context: In August 2021, Merck & Co.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves long-acting injectable for schizophrenia and bipolar disorder

European Pharmaceutical Review

Rykindo ® was approved for marketing in China in 2021 for the treatment of schizophrenia. An open-label pharmacokinetic and safety study of LY03004 evaluated an escalating single intramuscular injection in stable patients with schizophrenia or schizoaffective disorder. Promising schizophrenia drug faces tough competition.

article thumbnail

Current and future players in the lupus market

Pharmaceutical Technology

The management of SLE and LN consists largely of treatment options that are based on highly efficacious steroids or immune-suppressive therapy with an undesirable safety profile, which includes accrued organ damage, infections and cancer.

Marketing 111
article thumbnail

Clarivate Integrates Dialog Solutions Products and Services into Life Sciences & Healthcare Portfolio

Clarivate

Following the acquisition of Dialog Solutions as part of the ProQuest M&A in December 2021, Dialog Solutions products and services will be folded into the Clarivate portfolio of offerings for Life Sciences & Healthcare. Today, the Dialog Solutions brand has been integrated into Clarivate.

article thumbnail

Lupkynis approved for the treatment of LN in the EU and UK

Pharmaceutical Technology

Overall, Aurinia’s Lupkynis is expected to face tough competition from Benlysta in LN, which received FDA approval in December 2020 and EMA approval in May 2021. However, the lack of in-person administration by physicians will likely also impact patient compliance.

article thumbnail

Newron says pivotal treatment-resistant schizophrenia trial is a go

pharmaphorum

The new pivotal study in TRS will run in parallel to Newron’s ongoing phase 3 trial (Study 008A) of evenamide versus placebo over four weeks in patients with schizophrenia, which started in September 2021 and is due to generate results in the first half of this year.